New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

If Ianalumab + eltrombopag (VAYHIT2) gains regulatory approval, what would make you consider its use for second-line therapy after glucocorticoid failure/relapse, given its potential hematologic toxicity?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Children's Hospital of Philadelphia

I would consider this in patients who have a more immunoinflammatory phenotype (perhaps with other autoantibodies or with a significant family history of autoinflammatory disease) or in patients who have significant bleeding symptoms and need rapid control of the disease.

How would you manage suspected MGRS in a patient refusing a kidney biopsy?

1 Answers

Mednet MemberInvited Expert
Nephrology · Johns Hopkins University

To diagnose MGRS, a biopsy is necessary. If a patient has M protein on serum protein electrophoresis (SPEP) but shows no evidence of paraprotein-mediated kidney disease, this indicates MGUS. In contrast, conditions like PGNMID are also paraprotein-mediated but can be caused by a small clone that is ...

Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey

I do not, as part of the standard of care, in part because of limitations of the ClonoSEQ assay in this setting, and in part because of a lack of clarity around how best to manage a positive. However, there are a number of sophisticated clinical trials exploring this question prospectively, with a f...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How would you treat a stage I fully resected double hit DLBCL?

1
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Jacksonville

In patients with fully resected DLBCL, I still give chemotherapy. That also applies to double-hit lymphomas. Limited-stage DHL does not seem to have a poorer prognosis than non-DHL, and intensive regimens do not make a difference. I would treat with RCHOP x 3-4 cycles. Torka et al., PMID 31945157 Lu...

Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · City of Hope

While the information presented was intriguing, it has not yet caused any change in my approach to initial therapy for MCL. I say this due to the fact that the IR arm did not seem better than BR, save for those with a P53 mutation. I have routinely avoided CIT in this patient population, so this inf...

In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?

2
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Abramson Cancer Center, Perelman School of Medicine University of Pennsylvania

The management of MCL for almost 2 decades was driven by extrapolated data from aggressive B-cell lymphoma. However, aggressive chemotherapy and stem cell transplantation have failed to produce a plateau on overall survival curves, and patients inevitably have relapsed. It is now clear that MCL, par...

What is your approach to treatment of mantle cell lymphoma in someone with a mutated gene downstream of the BTK receptor, such as mutated CARD11?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · City of Hope

For those with primary refractory MCL after a cBTKi, I would still not proceed with chemotherapy, given the limited data to support benefit after a patient progresses on a cBTKi. Only data thus far is with a bendamustine/cytarabine-based regimen, which, if/when they relapse, would potentially impact...

What is your approach to the management of chronic GI bleeding from AVMs in an elderly patient on DOAC for atrial fibrillation?

6
7 Answers

Mednet MemberInvited Expert
Cardiology · University of California, Davis Health

I would definitely strongly consider the left atrial appendage occlusion device in these patients. While usually these devices (such as Watchman) do require anticoagulation for about 45 days until the device has an endothelial layer form on it (we usually confirm with a CT scan or TEE), there are so...

Do you routinely use antifibrinolytics for patients with heavy menstrual bleeding who are already on hormonal therapy?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Children's Hospital of Philadelphia

Yes. Counsel patients about theoretical increased risk, but more recent studies do not support increased thrombotic risk with antifibrinolytics. Ker et al., PMID 39461793 Meschino et al., PMID 40680937 Muradashvili et al., PMID 41139079

Do you routinely screen and replace Vitamin D in patients with ITP?

1
1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Children's Hospital of Philadelphia

I do not generally screen for vitamin D deficiency in ITP patients, but do recommend that all patients undergo routine screening as recommended by the American Academy of Pediatrics (pediatric provider) and have vitamin D deficiency identified and managed as appropriate for age in general, regardles...